A single-center, randomized, single-blind, phase 4 study to evaluate the enhancement of mucosal immunity in infants through maternal vaccination during breastfeeding (MEALAC-01).

Status

Not yet recruiting

Phases

Phase 4

Study type

Interventional

Source

EU CTIS

Registry ID

CTIS2025-524862-12-00

Enrollment

120

Registered

2026-04-14

Start date

Unknown

Completion date

Unknown

Last updated

2026-04-14

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Measles

Brief summary

The level of binding antibodies against measles in breastmilk in vaccinated vs unvaccinated mothers, 5 times over 3 months.

Detailed description

Phenotype and activation of immune cells in breastmilk

Interventions

DRUGM-M-RvaxPro powder and solvent for suspension for injection Measles

DRUGmumps and rubella vaccine (live)

Eligibility

Sex/Gender

All

Age

0 Years to 64 Years

Design outcomes

Primary

Measure	Time frame
The level of binding antibodies against measles in breastmilk in vaccinated vs unvaccinated mothers, 5 times over 3 months.	—

Secondary

Measure	Time frame
Phenotype and activation of immune cells in breastmilk	—

Outcome results

None listed

Source: EU CTIS · Data processed: Apr 15, 2026